ReviewMolecular cancer2025
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.
Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Double-coated PLGA nanoparticles with hierarchical surface architecture for CD44-targeted siRNA delivery.Drug delivery and translational research · 2026Article
- Review
- RNA splicing in health and disease.Molecular biomedicine · 2026Review
- Dual-Gene Edited Extracellular Vesicles Remodel the Redox Homeostasis to Inhibit Ferroptosis in Intervertebral Disc Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Current landscape of RNA chemistry and delivery in cancer immunotherapy.RSC chemical biology · 2026Review
- miRBind2 enables sequence-only prediction of miRNA binding and transcript repression.Bioinformatics (Oxford, England) · 2026Article
- The evolution of cancer therapeutics: from "undruggable" to "drugged".Translational cancer research · 2026Article
- ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities.Cellular & molecular biology letters · 2026Review
- Prognostic RNA-splicing archetypes in breast cancer identified by extended pre-training of histopathology foundation models.Nature communications · 2026Article
- LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Molecular Stability as a Translational Gate: A Structured Framework for Target Validation in Genetic Cardiomyopathy.Cureus · 2026Review
- Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure.Journal of ovarian research · 2026Review
- RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review.Pharmaceutics · 2026Review
- Platelet-derived non-coding RNAs as emerging contributors to autoimmune inflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- PDIA6 promotes the cell proliferation of ESCC by enhancing the disulfide bond formation in TRAF4.Cellular & molecular biology letters · 2026Article
- Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference.Biomolecules · 2026Review
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Integrative single-cell and machine-learning analysis identifies acBMC cancer · 2026Article
- RNA therapeutic targeting of recalcitrant and rare cancers.Exploration of targeted anti-tumor therapy · 2026Review
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy has been revolutionised by the emergence of RNA-based therapeutics, providing several strategies and mechanisms to regulate gene expression via messenger RNA (mRNA), small interfering RNA (siRNA), microRNAs (miRNA), antisense oligonucleotides (ASOs), and RNA aptamers. The present review highlights the recent advances in the preclinical development and clinical applications of RNA-based therapeutics, focusing on the delivery strategies, biological targets, and pharmacological optimisation, together with key clinical data. mRNA therapeutics, especially those adapted from vaccine platforms are being developed for the cancer immunotherapy and protein replacement, while siRNAs and ASOs enable highly specific gene silencing and splice correction. miRNA therapies show potential for diverse oncogenic pathway control, despite ongoing challenges in the delivery and specificity. RNA aptamers are obtaining attention as tumor-targeting agents in the drug delivery systems. Progress in lipid nanoparticles, chemical modifications, and tissue-specific delivery has improved the stability and efficacy of these agents. Early-phase clinical trials report encouraging outcomes in both solid tumours and haematologic malignancies, particularly in overcoming resistance and modulating the tumor microenvironment (TME). Although challenges remain in scalability, immune activation, and deep-tumour penetration, RNA-based strategies are advancing towards integration into clinical oncology. Continued refinement of delivery technologies and targeted trial designs will be critical for translating these therapies into effective, personalized cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.